VIOLIN: Vaccine Investigation and Online Information Network

KLK3
Gene Name	KLK3
Sequence Strain (Species/Organism)	Homo sapiens
NCBI Gene ID	354
NCBI Protein GI	71834853
Genbank Accession	AC011523
Protein Accession	NP_001025218
Taxonomy ID	9606
Chromosome No	19
Gene Starting Position	50854914
Gene Ending Position	50860763
Gene Strand (Orientation)	+
Protein Name	transcript variant 3
Protein pI	7.55
Protein Weight	23836.77
Protein Length	238
Protein Note	Also known as APS; PSA; hK3; KLK2A1
DNA Sequence	>NC_000019.10:50854914-50860763 Homo sapiens chromosome 19, GRCh38.p12 Primary Assembly CAGCCCCAAGCTTACCACCTGCACCCGGAGAGCTGTGTCACCATGTGGGTCCCGGTTGTCTTCCTCACCC TGTCCGTGACGTGGATTGGTGAGAGGGGCCATGGTTGGGGGGATGCAGGAGAGGGAGCCAGCCCTGACTG TCAAGCTGAGGCTCTTTCCCCCCCAACCCAGCACCCCAGCCCAGACAGGGAGCTGGGCTCTTTTCTGTCT CTCCCAGCCCCACTCCAAGCCCATACCCCCAGCCCCTCCATATTGCAACAGTCCTCACTCCCACACCAGG TCCCCGCTCCCTCCCACTTACCCCAGAACTTTCTCCCCATTGCCCAGCCAGCTCCCTGCTCCCAGCTGCT TTACTAAAGGGGAAGTTCCTGGGCATCTCCGTGTTTCTCTTTGTGGGGCTCAAAACCTCCAAGGACCTCT CTCAATGCCATTGGTTCCTTGGACCGTATCACTGGTCCACCTCCTGAGCCCCTCAATCCTATCACAGTCT ACTGACTTTTCCCATTCAGCTGTGAGTGCCCAACCCTATCCCAGAGACCTTGATGCTTGGCCTCCCAATC TTGCCCTAGGATACCCAGATGCCAACCAGACACCTCCTTCTTCCTAGCCAGGCTATCTGGCCTGAGACAA CAAATGGGTCCCTCAGTCTGGCAATGGGACTCTGAGAACTCCTCATTCCCTGACTCTTAGCCCCAGACTC TTCATTCAGTGGCCCACATTTTCCTTAGGAAAAACATGAGCATCCCCAGCCACAACTGCCAGCTCTCTGA TTCCCCAAATCTGCATCCTTTTCAAAACCTAAAAACAAAAAGAAAAACAAATAAAACAAAACCAACTCAG ACCAGAACTGTTTTCTCAACCTGGGACTTCCTAAACTTTCCAAAACCTTCCTCTTCCAGCAACTGAACCT CGCCATAAGGCACTTATCCCTGGTTCCTAGCACCGCTTATCCCCTCAGAATCCACAACTTGTACCAAGTT TCCCTTCTCCCAGTCCAAGACCCCAAATCACCACAAAGGACCCAATCCCCAGACTCAAGATATGGTCTGG GCGCTGTCTTGTGTCTCCTACCCTGATCCCTGGGTTCAACTCTGCTCCCAGAGCATGAAGCCTCTCCACC AGCACCAGCCACCAACCTGCAAACCTAGGGAAGATTGACAGAATTCCCAGCCTTTCCCAGCTCCCCCTGC CCATGTCCCAGGACTCCCAGCCTTGGTTCTCTGCCCCCGTGTCTTTTCAAACCCACATCCTAAATCCATC TCCTATCCGAGTCCCCCAGTTCCTCCTGTCAACCCTGATTCCCCTGATCTAGCACCCCCTCTGCAGGTGC TGCACCCCTCATCCTGTCTCGGATTGTGGGAGGCTGGGAGTGCGAGAAGCATTCCCAACCCTGGCAGGTG CTTGTGGCCTCTCGTGGCAGGGCAGTCTGCGGCGGTGTTCTGGTGCACCCCCAGTGGGTCCTCACAGCTG CCCACTGCATCAGGAAGTGAGTAGGGGCCTGGGGTCTGGGGAGCAGGTGTCTGTGTCCCAGAGGAATAAC AGCTGGGCATTTTCCCCAGGATAACCTCTAAGGCCAGCCTTGGGACTGGGGGAGAGAGGGAAAGTTCTGG TTCAGGTCACATGGGGAGGCAGGGTTGGGGCTGGACCACCCTCCCCATGGCTGCCTGGGTCTCCATCTGT GTTCCTCTATGTCTCTTTGTGTCGCTTTCATTATGTCTCTTGGTAACTGGCTTCGGTTGTGTCTCTCCGT GTGACTATTTTGTTCTCTCTCTCCCTCTCTTCTCTGTCTTCAGTCTCCATATCTCCCCCTCTCTCTGTCC TTCTCTGGTCCCTCTCTAGCCAGTGTGTCTCACCCTGTATCTCTCTGCCAGGCTCTGTCTCTCGGTCTCT GTCTCACCTGTGCCTTCTCCCTACTGAGCACACGCATGGGATGGGCCTGGGGGGACCCTGAGAAAAGGAA GGGCTTTGGCTGGGCGCGGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCAAGGCAGGTAGATCA CCTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACTGGTGAAACCCCATCTCTACTAAAAATACAAAAAA TTAGCCAGGCGTGGTGGCGCATGCCTGTAGTCCCAGCTACTCAGGAGGCTGAGGGAGGAGAATTGCTTGA ACCTGGGAGGTGGAGGTTGCAGTGAGCCGAGACCGTGCCACTGCACTCCAGCCTGGGTGACAGAGTGAGA CTCCGCCTCAAAAAAAAAAAAAAAAAAAAAGAAAAGAAAAGAAAAGAAAAGGAAGTGTTTTATCCCTGAT GTGTGTGGGTATGAGGGTATGAGAGGGCCCCTCTCACTCCATTCCTTCTCCAGGACATCCCTCCACTCTT GGGAGACACAGAGAAGGGCTGGTTCCAGCTGGAGCTGGGAGGGGCAATTGAGGGAGGAGGAAGGAGAAGG GGGAAGGAAAACAGGGTATGGGGGAAAGGACCCTGGGGAGCGAAGTGGAGGATACAACCTTGGGCCTGCA GGCCAGGCTACCTACCCACTTGGAAACCCACGCCAAAGCCGCATCTACAGCTGAGCCACTCTGAGGCCTC CCCTCCCCAGCGGTCCCCACTCAGCTCCAAAGTCTCTCTCCCTTTTCTCTCCCACACTCTATCATCCCCC GGATTCCTCTCTACTTGGTTCTCATTCTTCCTTTGACTTCCTGCTTCCCTTTCTCATTCATCTGTTTCTC ACTTTCTGCCTGGTTTTGTTCTTCTCTCTCTCTTTCTCTGGCCCATGTCTGTTTCTCTATGTTTCTGTCT TTTCTTTCTCATCCTGTGTATTTTCGGCTCACCTTGTTTGTCACTGTTCTCCCCTCTGCCCTTTCATTCT CTCTGTCCTTTTACCCTCTTCCTTTTTCCCTTGGTTTCTCTCAGTTTCTGTATCTGCCCTTCACCCTCTC ACACTGCTGTTTCCCAACTCGTTGTCTGTATTTTTGGCCTGAACTGTGTCTTCCCCAACCCTGTGTTTTT CTCACTGTTTCTTTTTCTCTTTTGGAGCCTCCTCCTTGCTCCTCTGTCCCTTCTCTCTTTCCTTATCATC CTCGCTCCTCATTCCTGCGTCTGCTTCCTCCCCAGCAAAAGCGTGATCTTGCTGGGTCGGCACAGCCTGT TTCATCCTGAAGACACAGGCCAGGTATTTCAGGTCAGCCACAGCTTCCCACACCCGCTCTACGATATGAG CCTCCTGAAGAATCGATTCCTCAGGCCAGGTGATGACTCCAGCCACGACCTCATGCTGCTCCGCCTGTCA GAGCCTGCCGAGCTCACGGATGCTGTGAAGGTCATGGACCTGCCCACCCAGGAGCCAGCACTGGGGACCA CCTGCTACGCCTCAGGCTGGGGCAGCATTGAACCAGAGGAGTGTACGCCTGGGCCAGATGGTGCAGCCGG GAGCCCAGATGCCTGGGTCTGAGGGAGGAGGGGACAGGACTCCTAGGTCTGAGGGAGGAGGGCCAAGGAA CCAGGTGGGGTCCAGCCCACAACAGTGTTTTTGCCTGGCCCGTAGTCTTGACCCCAAAGAAACTTCAGTG TGTGGACCTCCATGTTATTTCCAATGACGTGTGTGCGCAAGTTCACCCTCAGAAGGTGACCAAGTTCATG CTGTGTGCTGGACGCTGGACAGGGGGCAAAAGCACCTGCTCGGTGAGTCATCCCTACTCCCAAGATCTTG AGGGGAAAGGTGAGTGGGGACCTTAATTCTGGGCTGGGGTCTAGAAGCCAACAAGGCGTCTGCCTCCCCT GCTCCCCAGCTGTAGCCATGCCACCTCCCCGTGTCTCATCTCATTCCCTCCTTCCCTCTTCTTTGACTCC CTCAAGGCAATAGGTTATTCTTACAGCACAACTCATCTGTTCCTGCGTTCAGCACACGGTTACTAGGCAC CTGCTATGCACCCAGCACTGCCCTAGAGCCTGGGACATAGCAGTGAACAGACAGAGAGCAGCCCCTCCCT TCTGTAGCCCCCAAGCCAGTGAGGGGCACAGGCAGGAACAGGGACCACAACACAGAAAAGCTGGAGGGTG TCAGGAGGTGATCAGGCTCTCGGGGAGGGAGAAGGGGTGGGGAGTGTGACTGGGAGGAGACATCCTGCAG AAGGCGGGAGTGAGCAAACACCTGCCGCAGGGGAGGGGAGGGCCCTGCGGCACCTGGGGGAGCAGAGGGA ACAGCATCTGGCCAGGCCTGGGAGGAGGGGCCTAGAGGGCGTCAGGAGCAGAGAGGAGGTTGCCTGGCTG GAGTGAAGGATCGGGGCAGGGTGCGAGAGGGAAGAAAGGACCCCTCCTGCAGGGCCTCACCTGGGCCACA GGAGGACACTGCTTTTCCTCTGAGGAGTCAGGAACTGTGGATGGTGCTGGACAGAAGCAGGACAGGGCCT GGCTCAGGTGTCCAGAGGCTGCCGCTGGCCTCCCTATGGGATCAGACTGCAGGGAGGGAGGGCAGCAGGG ATGTGGAGGGAGTGATGATGGGGCTGACCTGGGGGTGGCTCCAGGCATTGTCCCCACCTGGGCCCTTACC CAGCCTCCCTCACAGGCTCCTGGCCCTCAGTCTCTCCCCTCCACTCCATTCTCCACCTACCCACAGTGGG TCATTCTGATCACCGAACTGACCATGCCAGCCCTGCCGATGGTCCTCCATGGCTCCCTAGTGCCCTGGAG AGGAGGTGTCTAGTCAGAGAGTAGTCCTGGAAGGTGGCCTCTGTGAGGAGCCACGGGGACAGCATCCTGC AGATGGTCCTGGCCCTTGTCCCACCGACCTGTCTACAAGGACTGTCCTCGTGGACCCTCCCCTCTGCACA GGAGCTGGACCCTGAAGTCCCTTCCCCACCGGCCAGGACTGGAGCCCCTACCCCTCTGTTGGAATCCCTG CCCACCTTCTTCTGGAAGTCGGCTCTGGAGACATTTCTCTCTTCTTCCAAAGCTGGGAACTGCTATCTGT TATCTGCCTGTCCAGGTCTGAAAGATAGGATTGCCCAGGCAGAAACTGGGACTGACCTATCTCACTCTCT CCCTGCTTTTACCCTTAGGGTGATTCTGGGGGCCCACTTGTCTGTAATGGTGTGCTTCAAGGTATCACGT CATGGGGCAGTGAACCATGTGCCCTGCCCGAAAGGCCTTCCCTGTACACCAAGGTGGTGCATTACCGGAA GTGGATCAAGGACACCATCGTGGCCAACCCCTGAGCACCCCTATCAACCCCCTATTGTAGTAAACTTGGA ACCTTGGAAATGACCAGGCCAAGACTCAAGCCTCCCCAGTTCTACTGACCTTTGTCCTTAGGTGTGAGGT CCAGGGTTGCTAGGAAAAGAAATCAGCAGACACAGGTGTAGACCAGAGTGTTTCTTAAATGGTGTAATTT TGTCCTCTCTGTGTCCTGGGGAATACTGGCCATGCCTGGAGACATATCACTCAATTTCTCTGAGGACACA GATAGGATGGGGTGTCTGTGTTATTTGTGGGGTACAGAGATGAAAGAGGGGTGGGATCCACACTGAGAGA GTGGAGAGTGACATGTGCTGGACACTGTCCATGAAGCACTGAGCAGAAGCTGGAGGCACAACGCACCAGA CACTCACAGCAAGGATGGAGCTGAAAACATAACCCACTCTGTCCTGGAGGCACTGGGAAGCCTAGAGAAG GCTGTGAGCCAAGGAGGGAGGGTCTTCCTTTGGCATGGGATGGGGATGAAGTAAGGAGAGGGACTGGACC CCCTGGAAGCTGATTCACTATGGGGGGAGGTGTATTGAAGTCCTCCAGACAACCCTCAGATTTGATGATT TCCTAGTAGAACTCACAGAAATAAAGAGCTGTTATACTGT
Protein Sequence	>NP_001025218.1 prostate-specific antigen isoform 3 preproprotein [Homo sapiens] MWVPVVFLTLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHPQWVLTAAHCIRNK SVILLGRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRLSEPAELTDAVKVMD LPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQKVTKFMLCAGRWTGGKSTCS WVILITELTMPALPMVLHGSLVPWRGGV
Molecule Role	Protective antigen
Molecule Role Annotation	Plasmid expressing human PSA gene (phPSA) was delivered in vivo by intra-muscular electroporation, to induce effective anti-tumour immune responses against prostate antigen expressing tumours. Groups of male C57 BL/6 mice received intra-muscular injections of phPSA plasmid. One week after last vaccination, the mice were challenged subcutaneously with TRAMPC1/hPSA (prostate cancer cell line stably expressing human PSA) and tumour growth was monitored. The phPSA vaccine therapy significantly delayed the appearance of tumours and resulted in prolonged survival of the animals (Ahmad et al., 2010).
Related Vaccines(s)	APC8015F , Fowlpox Virus Vaccine , Fowlpox-PSA-TRICOM Vaccine , GVAX Cancer Vaccine , MVA-PSA/PAP Prostate Cancer Vaccine , Prostate cancer DNA vaccine psig-3P-Fc encoding 3P(hPSM, hPAP, or hPSA)-Fc fusion protein , Prostate Tumor Antigen-activated Autologous Dendritic Cell Vaccine , PROSTVAC-Contaminated W/ BVDV , PSA Prostate Cancer Vaccine , PSA RNA-Pulsed Dendritic Cell Vaccine , PSA-OP Peptide Vaccine , PSA:154-163(155L) Peptide Vaccine , PSMA/TARP Peptide Vaccine , pVAXrcPSAv53l DNA Vaccine , Recombinant Fowlpox-Prostate Specific Antigen Vaccine , Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine , Recombinant Vaccinia DF3/MUC1 Vaccine , Recombinant Vaccinia PSA Vaccine , Recombinant Vaccinia-Prostate Specific Antigen Vaccine , Recombinant Vaccinia-PSA/PSMA Vaccine , rF-PSA/PSMA/TRICOM Vaccine , Rilimogene-galvacirepvec Vaccine
References

KLK3